Identification of surrogate markers for a marketed drug is important in monitoring the efficacy or safety after a patient uses the drug. In this article, we clarify the statistical definitions of the surrogate endpoint and surrogate marker and introduce the concept of the validity and efficiency of a surrogate marker. We also review some existing methods and suggest the proportion of information gain is appropriate to be used to evaluate the validity of a surrogate marker.
TempleRJ. A regulatory authority’s opinion about surrogate endpoints. In: NimmoWSTuckerGT (eds) Clinical Measurement in Drug Evaluation (1st edn). Wiley, New York, 1995, pp. 3–22.
3.
QuY. Evaluation of a surrogate marker: Validity and efficiency. Stat Med2013; 32: 1995–2000.
4.
PrenticeRL. Surrogate endpoints in clinical trials: Definitions and operational criteria. Stat Med1989; 8: 431–40.
5.
FreedmanLSGraubardBISchatzkinA. Statistical validation of intermediate endpoints for chronic diseases. Stat Med1992; 11: 167–78.
6.
BuyseMMolenberghsG. Criteria for the validation of surrogate endpoints in randomized experiments. Biometrics1998; 54: 1014–29 (Erratum in Biometrics 2000; 56: 324).
7.
QuYCaseM. Quantifying the effect of the surrogate marker by information gain. Biometrics2007; 63: 958–62.
8.
LiWQuY. Adjustment for the measurement error in evaluating biomarkers. Stat Med2010; 29: 2338–46.
9.
LiWQuYKulkarniPM. Sensitivity in statistical evaluation of biomarkers. Stat Med2013; doi: 10.1002/sim.5794 (Epub ahead of print 16 April).
